2023 ASCO中國之聲 | 結直腸癌領域壁報部分共17項中國研究入選！

一年一度的全球腫瘤界盛會-美國臨床腫瘤學會（ASCO）年會將于當地時間6月2日-6月6日召開。ASCO年會是世界上規模最大、學術水平最高、最具權威的臨床腫瘤學會議，致力于癌癥的預防、治療和改善患者管理，以展示腫瘤的基礎研究和臨床最新研究為特點，討論當前國際先進的治療方法。

隨著中國臨床研究在腫瘤領域的快速成長，中國在世界腫瘤領域中也發揮著日益重要的作用。此次會議上，中國結直腸癌領域Poster Session共入選17項。期待中國專家在ASCO年會上展現風采！

標題：A deep learning model for the prediction of microsatellite instability and pathogenic POLE mutations in colorectal cancer using histopathologic images.

報告人：許婷

單位：北京大學腫瘤醫院

標題：A phase 1 dose escalation study of GCC19CART: A novel coupled CAR therapy for patients with metastatic colorectal cancer.

報告人：Lei Xiao

單位：斯丹賽(上海)生物醫藥技術有限公司

標題：A phase Ib/II study to evaluate surufatinib combined with camrelizumab and chemotherapy in the second-line treatment of advanced colorectal cancer: Phase Ib results.

報告人：李晟

單位：江蘇省腫瘤醫院

標題：Novel GUCY2C targeting CAR-T therapy: Efficacy in advanced colorectal cancer.

報告人：Qianyu Zhang

單位：安徽省腫瘤醫院

標題：A phase II study of regorafenib plus sintilimab as salvage-line treatments in non–MSI-H metastatic colorectal cancer (mCRC).

報告人：劉銳

單位：天津醫科大學腫瘤醫院

標題：Safety and efficacy of D-1553 in KRAS G12C-mutated colorectal cancer: Results from a phase I/II study.

報告人：阮丹云

單位：中山大學腫瘤防治中心

標題：Deep learning-derived spatial organization features on histopathology images to predict prognosis in patients with colorectal liver metastasis, after hepatectomy.

報告人：王鑫

單位：香港中文大學

標題：Efficacy and safety of fruquintinib plus investigator’s choice of chemotherapy as second-line therapy in metastatic colorectal cancer: A multicenter, single-arm phase 2 trial.

報告人：趙文思

單位：武漢大學人民醫院

標題：Efficacy and safety of irinotecan-eluting HepaSphere transarterial chemoembolization combined with hepatic arterial infusion chemotherapy for unresectable colorectal liver metastases.

報告人：Aiwei Feng

單位：北京大學腫瘤醫院

標題：Efficacy and safety of IBI351 (GFH925) monotherapy in metastatic colorectal cancer harboring KRASG12C mutation: Preliminary results from a pooled analysis of two phase I studies.

報告人：袁瑛

單位：浙江大學醫學院附屬第二醫院

標題：VIC regimen (vemurafenib/irinotecan/cetuximab) versus bevacizumab plus chemotherapy as first-line treatment for BRAF V600E-mutated advanced colorectal cancer.

報告人：Yijiao Chen

單位：復旦大學附屬中山醫院

標題：The role of image-guided volume-adapted high-dose-rate endorectal brachytherapy boost in total neoadjuvant treatment of distal locally advanced rectal cancer.

報告人：Huangang Jiang

單位：武漢大學中南醫院

標題：Efficacy and safety of mFOLFOX6 with apatinib as postoperative adjuvant chemotherapy in stage IIIB or IIIC colorectal cancer.

報告人：顧曉冬

單位：復旦大學附屬華山醫院

標題：Prophylactic hyperthermic intraperitoneal chemotherapy in T4 colorectal cancer: Can it improve the oncologic prognosis?

報告人：孫立峰

單位：浙江大學醫學院附屬第二醫院

標題：Efficacy and safety of KN026 in combination with KN046 in patients with locally advanced unresectable or metastatic HER2-positive other solid tumors.

報告人：龔繼芳

單位：北京大學腫瘤醫院

標題：PACE: A phase III trial of CAPOX versus anti-PD-1 inhibitor as adjuvant therapy for patients with dMMR/MSI-H stage III colon cancer.

報告人：Zhenlin Hou

單位：中山大學腫瘤防治中心

標題：Neoadjuvant short-course radiotherapy followed by chemotherapy plus camrelizumab versus long-course chemoradiotherapy followed by chemotherapy for patients with locally advanced rectal cancer: A randomized, multicenter, open-label phase 3 trial (Union).

報告人：林振宇

單位：華中科技大學同濟醫學院附屬協和醫院